Pfizer Inc. (KASE:PFE_KZ)
Kazakhstan · Delayed Price · Currency is KZT · Price in USD | Market Cap | 75.16T +3.8% |
| Revenue (ttm) | 28.16T +1.3% |
| Net Income | 1.79T -59.0% |
| EPS | 314.88 -59.3% |
| Shares Out | n/a |
| PE Ratio | 41.61 |
| Forward PE | 10.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,570 |
| Open | 29.83 |
| Previous Close | 30.56 |
| Day's Range | 28.80 - 29.83 |
| 52-Week Range | 23.00 - 31.44 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer price target raised to $34 from $33 at Freedom Broker
Freedom Broker raised the firm’s price target on Pfizer (PFE) to $34 from $33 and keeps a Buy rating on the shares. Q3 results were “strong,” with revenue and EPS…
Pfizer downgraded to Hold from Buy at DZ Bank
DZ Bank downgraded Pfizer (PFE) to Hold from Buy with a $33 price target
Pfizer price target raised to $33 from $31 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Pfizer (PFE) to $33 from $31 and keeps a Buy rating on the shares.
Pfizer (PFE) Stock Looks Attractive for Income Investors
Pfizer ($PFE) stock looks attractive for income investors because of its well-covered dividend and modest valuation. The drug maker’s shares have outperformed the S&P 500 (SPX) in 2026, mirroring the…
Pfizer price target raised to $35 from $33 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Pfizer (PFE) to $35 from $33 and keeps an Outperform rating on the shares. The firm believes the earnings potential…
Pfizer price target lowered to $26 from $28 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Pfizer (PFE) to $26 from $28 and keeps an Equal Weight rating on the shares.
Pfizer price target raised to $28 from $25 at RBC Capital
RBC Capital raised the firm’s price target on Pfizer (PFE) to $28 from $25 and keeps a Sector Perform rating on the shares after its Q3 earnings beat and guidance…
Pfizer price target raised to $30 from $27 at UBS
UBS analyst Michael Yee raised the firm’s price target on Pfizer (PFE) to $30 from $27 and keeps a Neutral rating on the shares.
United Therapeutics announces buydown of Ralinepag royalty
United Therapeutics (UTHR) announced that it has entered into an amendment with Arena Pharmaceuticals, a subsidiary of Pfizer (PFE), which eliminates all royalty obligations under its exclusive licens...
Pfizer price target raised to $30 from $27 at Citi
Citi raised the firm’s price target on Pfizer (PFE) to $30 from $27 and keeps a Neutral rating on the shares. The firm views the company’s Q3 report as showing…
Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market
CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.
Midday Fly By: Apple warns of lower margins, Pfizer reports ‘beat and raise’
The major averages were mixed near noon, with the Dow fractionally lower but the S&P 500 and Nasdaq higher, as investors digest the latest spate of corporate earnings reports. Apple…
Pfizer Earnings Call Transcript: Q3 2026
Q3 revenue reached $16.6B, with non-COVID products up 7% operationally and launched/acquired products up 32%. FY26 revenue and adjusted EPS guidance rose; LOEs, pricing and pipeline execution remain key drivers and risks.
Pfizer Slides: Q3 2026
Pfizer has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Pfizer Earnings release: Q3 2026
Pfizer released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Pfizer Prepared remarks: Q3 2026
Pfizer filed a regulatory document on November 3, 2026 disclosing important business information.
Pfizer Quarterly report: Q3 2026
Pfizer has published its Q3 2026 quarterly earnings report on November 3, 2026.
Pfizer (PFE) vs. AstraZeneca (AZN): Which Pharma Stock Offers a Better Dividend?
Pfizer ($PFE) and AstraZeneca ($AZN) are two pharmaceutical companies that offer dividends. Both offer dividend yields above the broader market, but Pfizer offers quarterly dividends, while AstraZenec...
Pfizer Stock (PFE) Flat Despite Q3 Beat and Raised 2026 Sales Outlook — Here’s Why
Pfizer shares ($PFE) traded flat in Tuesday’s pre-market session even after the U.S. pharma giant beat Q3 earnings expectations and raised its 2026 sales forecast. The company now expects full-year…
Pfizer Raises Forecast on Momentum With New Products
Pfizer boosted its guidance for the year, citing momentum in newly-launched and acquired products that helped offset declining sales for its Covid-19 vaccine and treatments.
Pfizer Finds Life Beyond the Pandemic as Earnings Top Estimates
Pfizer boosts full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products.
Pfizer hikes full-year outlook, taps company veteran as new CFO
Pfizer reported third-quarter results that topped estimates and hiked its full-year outlook, citing its "strong year-to-date performance" and ongoing cost cuts. Pfizer also announced that Cecile Gueg...
Pfizer reports Q3 adjusted EPS 87c consensus 73c
Reports Q3 revenue $16.6B, consensus $15.88B. Dr. Albert Bourla, Chairman and CEO of Pfizer (PFE): “Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing...
Pfizer raises FY26 adjusted EPS view to $2.95-$3.05 from $2.80-$3.00
FY26 consensus $2.96. Raises FY26 revenue view to $62B-$64B from $60.5B-$62.5B, consensus $62.23B.
Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis
Pfizer raised its annual forecasts on Tuesday as strong demand for its cancer drugs and blockbuster blood thinner Eliquis helped the drugmaker post better-than-expected third-quarter results.